Researchers review real-world switch to self-injected IBD drug
NCT ID NCT07123350
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks back at medical records of 120 adults with Crohn's disease or ulcerative colitis who switched from intravenous to subcutaneous (under-the-skin) vedolizumab. Researchers want to see what dosing patterns doctors used and whether patients achieved remission. No new treatments are being tested; the goal is to learn from real-world experience.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHN'S DISEASE (CD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37211, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a tree mushroom drink calm inflammatory bowel disease?
- Could a new pill tame inflammatory bowel disease? early safety trial begins
- A simple hospital checklist could flag hidden malnutrition in kids with IBD
- Can a new pill tame ulcerative colitis Flare-Ups?
- Can a mediterranean diet and Time-Restricted eating tame gut inflammation?
- Could a new pill tame ulcerative colitis? a First-in-Human trial aims to find out